 BURBANK, Calif., June 23, 2021 GLOBE NEWSWIRE -- via NewMediaWire Medolife Rx, Inc. Medolife, a global integrated biopharmaceutical company with RD, manufacturing, and consumer products, which is a majority owned subsidiary of Quanta, Inc. OTC PINK: QNTA, announced today that the Company has received a response from the U.S. Food and Drug Administration FDA relating to its Pre-Investigational New Drug Pre-IND filing on its lead drug candidate Escozine for the treatment of the SARS-CoV-2 COVID-19 virus. The response validated the Companys clinical study conducted in the Dominican Republic DR and outlined next steps for its approval process in the US. 